ROCHESTER, NY – Vaccinex Inc., a clinical stage biotechnology company focused on the development of novel immune-based therapeutics, announced today that President and CEO Dr. Maurice Zauderer will present information about Vaccinex’s most advanced therapeutic antibody, VX15/2503, on Thursday, March 31st at the BIO-Windhover Pharmaceutical Strategic Outlook Conference in New York. VX15/2503 antibody targets a molecule, SEMA4D, that positively regulates activation and migration of multiple cell types involved in inflammation, angiogenesis, and tumor invasion. Vaccinex has initiated a phase I clinical trial of VX15/2503 antibody in cancer patients. Because SEMA4D also negatively regulates myelination and axonal regeneration, a second clinical trial is planned in patients with neurodegenerative disease.
About Vaccinex, Inc.
Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of novel therapeutic antibodies. Utilizing its patented ActivMAb® antibody discovery technology, Vaccinex has developed the only library-based antibody discovery technology capable of directly expressing bivalent, fully human antibodies in mammalian cells. The company is building an impressive pipeline of therapeutic antibodies with the potential for effectively treating various autoimmune diseases and cancers. For additional information, please visit the company’s website at www.vaccinex.com.